Redefining Parkinson's Disease | Kathleen Poston

Today on the show, a new understanding of Parkinson's disease.

Parkinson's disease is one of the most common neurodegenerative disorders — right after Alzheimer's disease. It's familiar to many as a movement disorder: people with the disease develop difficulties with voluntary control of their bodies. But the real story is much more complicated.

This week, we speak with Kathleen Poston, a Stanford neurologist who is at the forefront of efforts to redefine Parkinson's disease and related disorders based on their underlying biology — not just their symptoms. As Poston says: "The biology is the disease." 

Join us to learn about exciting advances in our ability to detect the brain pathology driving these disorders much earlier, even before symptoms arise, and how this is opening doors for early intervention and — hopefully — prevention.

Learn More

• Poston Lab at Stanford Medicine
• Lewy Body Dementia Research Center of Excellence at Stanford
• Understanding Parkinson's Disease: Stanford's Dr. Kathleen Poston on latest advances (CBS News Bay Area - Video)
• A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research (The Lancet - Neurology, 2024)
• International Working Group Proposes New Framework for Defining Parkinson Disease Based on Biology, Not Symptoms (Neurology Live article)

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute and Knight Initiative for Brain Resilience. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.